Puma Biotechnology Aktie

Kaufen

Verkaufen

2,93 EUR +0,04 EUR +1,45 %

14:05:02

BER

3,32 USD +0,03 USD +0,76 %

03.06.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.144,43 Mio. EUR

KGV4,95Div. Rendite0,00%

WKNA1J643

ISINUS74587V1070

SymbolPBYI

Puma Biotechnology Aktien News

Sortieren:Datum Meistgelesen

06.11.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02.11.23BusinesswirePuma Biotechnology Reports Third Quarter 2023 Financial Results

19.10.23BusinesswirePuma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

04.10.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

21.09.23BusinesswirePuma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

31.08.23BusinesswirePuma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

08.08.23BusinesswirePuma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

03.08.23BusinesswirePuma Biotechnology Reports Second Quarter Financial Results

20.07.23BusinesswirePuma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

06.06.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

05.05.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04.05.23BusinesswirePuma Biotechnology Reports First Quarter Financial Results

20.04.23BusinesswirePuma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

11.04.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

14.03.23BusinesswirePuma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

03.03.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02.03.23BusinesswirePuma Biotechnology Reports Fourth Quarter and Full Year Financial Results

28.02.23BusinesswirePuma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference

16.02.23BusinesswirePuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

07.02.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

01.02.23BusinesswirePuma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

12.01.23BusinesswirePuma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference

11.01.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

09.01.23BusinesswirePuma Biotechnology Releases Updated Corporate Presentation

08.12.22BusinesswirePuma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium

05.12.22BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

03.11.22BusinesswirePuma Biotechnology Reports Third Quarter 2022 Financial Results

02.11.22BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

27.10.22BusinesswirePuma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium

20.10.22BusinesswirePuma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

04.10.22BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

20.09.22BusinesswirePuma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor

11.09.22BusinesswirePuma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

06.09.22BusinesswirePuma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference

02.09.22BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04.08.22BusinesswirePuma Biotechnology Reports Second Quarter 2022 Financial Results

21.07.22BusinesswirePuma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

06.07.22BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

07.06.22BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

06.06.22BusinesswirePuma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Puma Biotechnology News

Puma Biotechnology News: auf dieser Seite finden Sie alle Puma Biotechnology News und Nachrichten zur Puma Biotechnology Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Puma Biotechnology News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Puma Biotechnology News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.